◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksG › GNS

Genus plc (GNS) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-16

Genus plc (GNS) operates in the Biotechnology industry and is headquartered in Basingstoke, United Kingdom with about 3,190 employees. Its market capitalization is roughly £1 billion. In the fiscal year ended 2025-06-30, GNS reported £673M in revenue.

Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development.

Interactive charts & full statements →

GNS Revenue & Earnings History — Annual Income Statement

Income statement2025-06-302024-06-302023-06-302022-06-30
Total Revenue£673M£669M£690M£593M
Gross Profit£179M£188M£148M
Operating Income (EBIT)£42M£6M£44M£51M

GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GNS Free Cash Flow History

Cash flow2025-06-302024-06-302023-06-302022-06-30
Dividends Paid(£21M)(£21M)(£21M)(£21M)

GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GNS Balance Sheet History

Balance sheet2025-06-302024-06-302023-06-302022-06-30
Total Assets£899M£988M£966M£1.0B
Total Liabilities£423M£474M£430M£446M

GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GNS viewer.

Other Companies in Biotechnology

← GNRCAll “G” companiesGNSS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.